An increasing variety of technologies are now available to investigators to manipulate individual genes or to monitor biological processes with precision. These technologies are crucial to the study of the molecular bases of skin diseases because they allow us to establish a clear, causative relationship between a gene and an observed phenotype. However, such technologies are often complicated and not available to many investigators involved in cutaneous biology and skin diseases research. In the Cell and Gene Modification Core, we will provide the following services: 1) Generate keratinocytes, fibroblasts, or other skin cells with targeted reporter genes or gene knockdowns. 2) Generate genetically defined skin or induced pluripotent stem cells by use of state-of-the-art genome editing technologies. 3) Provide consultation and training to investigators interested in employing cell-based models for skin research. We envision that genetically modified cells are likely to be derived from tissues obtained in the Tissue Procurement and Analysis Core (Core D) and further incorporated into animal and tissue models generated in the Animal Models and Tissue Engineering Core (Core C) to create relevant skin disease models. As such, services to be provided by the Cell and Gene Modification Core will significantly enhance the ability of Duke research community to carry out mechanism-based skin research.

Public Health Relevance

Skin diseases affect a large percentage of the population. The Cell and Gene Modification Core will facilitate mechanism-based skin disease research by allowing investigators to precisely examine the functions of genes and cells that play a role in skin biology and disease. This ability, in turn, will accelerate discovery and basic understanding that can lead to new therapies

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Klann, Tyler S; Crawford, Gregory E; Reddy, Timothy E et al. (2018) Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing. Methods Mol Biol 1767:447-480
Klann, Tyler S; Black, Joshua B; Gersbach, Charles A (2018) CRISPR-based methods for high-throughput annotation of regulatory DNA. Curr Opin Biotechnol 52:32-41
Chen, Yong; Moore, Carlene D; Zhang, Jennifer Y et al. (2017) TRPV4 Moves toward Center-Fold in Rosacea Pathogenesis. J Invest Dermatol 137:801-804
Polstein, Lauren R; Juhas, Mark; Hanna, Gabi et al. (2017) An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis. ACS Synth Biol 6:2003-2013
Suwanpradid, Jutamas; Holcomb, Zachary E; MacLeod, Amanda S (2017) Emerging Skin T-Cell Functions in Response to Environmental Insults. J Invest Dermatol 137:288-294
Liu, Xinjian; Li, Fang; Huang, Qian et al. (2017) Self-inflicted DNA double-strand breaks sustain tumorigenicity and stemness of cancer cells. Cell Res 27:764-783
Klann, Tyler S; Black, Joshua B; Chellappan, Malathi et al. (2017) CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol 35:561-568
Zhang, Xiaoling; Luo, Suju; Wu, Joseph et al. (2017) KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage. J Invest Dermatol 137:475-483
Ousterout, David G; Gersbach, Charles A (2016) The Development of TALE Nucleases for Biotechnology. Methods Mol Biol 1338:27-42
Li, Fang; Liu, Xinjian; Sampson, John H et al. (2016) Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. Cancer Res 76:5143-50

Showing the most recent 10 out of 26 publications